Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors.
GABA stands for Gamma-AminoBityric Acid, which is an inhibiting neurotransmitter in the central nervous system. The GABA Receptor family holds the major inhibitory neurotransmitter in the central nervous system.
The products based on the GABA Receptor program from Sage Therapeutics follow:
- Brexanalone (SAGE-547) is a compound developed for the treatment of postpartum depression. The compound is under Registration stage.
- SAGE-217 is a compound under clinical study for the treatment of major depressive disorder, postpartum depression, bipolar depression, insomnia, Parkinson’s disease, and essential tremor.
- SAGE-324 is a compound under the pre-clinical stage for the treatment of Parkinson’s disease, essential tremor, and Epileptiform disorder.
NMDA Receptor is the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor. The products under development using the NMDA Receptor program are as follows:
- SAGE-718 is a compound under clinical study for Anti-NMDA receptor encephalitis and NMDA hypofunction.
- SAGE-904 is a positive allosteric modulator under the IND-enabling studies.
We’ll discuss the details of these products in the following articles.
The iShares NASDAQ Biotechnology ETF (IBB) holds 0.9% of its total investments in Sage Therapeutics (SAGE), 0.7% in Ionis Pharmaceuticals (IONS), 1.8% in Incyte Corporation (INCY), and 8.3% in Gilead Sciences (GILD).